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1. Introduction 
The dual specificity phosphatases (DUSPs) are a subfamily within the protein tyrosine 
phosphatase (PTP) family, with the unique property of being able to hydrolyze phospho-
serine or phospho-threonine residues and phospho-tyrosine residues [1]. All DUSPs share 
the characteristic Class I PTP consensus sequence, D…HC(X)5RS/T, with C representing the 
essential catalytic cysteine [1]. Unlike other PTPs, DUSPs lack the phospho-tyrosine 
recognition domain, resulting in a shallower catalytic cleft, most likely enabling DUSPs to 
dephosphorylate all three residues (S/T/Y) [1]. In addition to protein substrates, the DUSP 
subfamily contains members that dephosphorylate additional substrates including lipids, 
nucleic acids, and sugars [2].  
DUSPs are regulators of multiple signaling pathways driving fundamental cell processes 
such as growth, proliferation, apoptosis, and migration, and as such they are often 
deregulated in a variety of diseases [2]. DUSPs can be further classified on substrate 
specificity and sequence homology, but all DUSPs share a highly conserved prototypical 
DUSP domain initially characterized in the Vaccinia virus’s VH1 gene [3]. The best-
characterized DUSPs include the MAP kinase phosphatases (MKP's), which directly 
antagonize the activating dual phosphorylation of mitogen activated protein kinases, and 
PTEN that functions to dephosphorylate phosphatidyl-inositol 3,4,5 triphosphate (PIP3), the 
product of PI3 kinase (PI3K) [2]. As these signaling pathways are intimately implicated in 
cancer initiation and progression, it is not surprising that their cognate phosphatases also 
functionally contribute to disease progression [2,4].  
In addition to DUSPs described above, the DUSP subfamily contains a distinct subgroup 
described as the atypical DUSPs [2,5]. In humans there are at least 16 DUSPs classified as 
atypical (Table 1) based on the lack of sequence similarity to better-characterized DUSPs 
and/or due to their substrate specificity [2,5]. Physiological substrates for several atypical  
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Table 1. The atypical DUSPs and their various aliases. 
DUSPs include proteins (MAPKs), nucleic aids (RNA), and phosphorylated carbohydrates 
(amylopectin and glycogen), but for many atypical DUSPs physiological substrates are 
unknown [2,5]. However, even for cases where phosphatase-substrate relationships are 
known, they are somewhat complicated by the fact that several DUSPs appear to function 
independently of their phosphatase activity and instead function as scaffolds in signal 
transduction pathways [6-8]. 
Several atypical DUSPs have been implicated in apoptosis and proliferation [2,5], but how 
the DUSPs contribute to these processes is largely also unknown. Emerging roles for 
atypical DUSPs in malignancy are beginning to be inferred from high throughput 
sequencing/ genomic approaches, which have demonstrated that, like MKP's and lipid 
phosphatases, the atypical DUSP genes are differentially expressed in a variety of cancers 
and may contribute to cancer initiation and/or progression [2,4,5]. The following sections 
present a current synthesis of what is known about how the atypical DUSPs function, and 
will focus specifically on how these proteins may contribute to cancer initiation and 
progression. Current gaps in knowledge on the function of these proteins in both normal 
and cancer cell biology is highlighted to hopefully inspire new research on these poorly 
understood proteins.  
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2. Atypical DUSPs currently implicated in cancer 
2.1. Laforin 
Due to alternative splicing of mRNA encoded by the epm2a gene, at least two isoforms of 
Laforin have been described that differ in their subcellular localization and phosphatase 
activity [9]. The major isoform encodes for a 331 amino acid protein containing a 
catalytically active DUSP domain and a N-terminal carbohydrate-binding module (CBM). 
Loss of function mutations of the major isoform are causative for Lafora’s disease, a fatal 
form of progressive myoclonus epilepsy that is thought to occur as a result of deregulated 
glycogen metabolism [10-13] with the accumulation of insoluble complex carbohydrates 
[14]. Laforin regulates glycogen metabolism, in part, by its ability to directly 
dephosphorylate phosphorylated carbohydrates including glycogen [14]. Loss of epm2a or 
mutations in epm2a that prevent glycogen binding or alter its phosphatase activity, 
contribute to Lafora’s disease [14,15]. Laforin also regulates glycogen metabolism in a 
phosphatase independent manner by functioning as an adapter protein to promote the 
ubiquitination of proteins involved in glycogen metabolism by recruiting Malin, an E3 
ubiquitin ligase [16]. Proteins regulating glycogen metabolism are often complexed with 
glycogen, as Laforin can bind glycogen and independently recruit Malin this provides an 
additional regulatory mechanism [16]. As a result, mutations in epm2a that disrupt the 
ability to bind Malin also contribute to Lafora’s disease [16]. Over the last several years, 
studies have revealed additional potential role(s) for Laforin in cancer development and/or 
progression where it most likely functions as a tumor suppressor, but may also contribute to 
cancer by promoting cell survival [17,18]. Here, we focus on potential roles of the major 
isoform in cancer, as it is the most studied. 
A role for Laforin as a tumor suppressor was demonstrated by the observation that 
immunocompromised mice lacking Laforin produce spontaneous lymphomas [19]. 
Additionally, Laforin mRNA and protein levels were reduced in murine and human 
primary lymphomas [19]. In addition to the roles of Laforin in glycogen metabolism and 
Lafora’s disease, Laforin regulates glycogen synthase kinase 3 (GSK3β) activity, a key 
signaling protein in the β-catenin/WNT signaling pathway [20] by removal of the inhibitory 
phosphate at Ser9 [21]. Cells lacking Laforin display decreased GSK3β activity resulting in 
increased cyclin D1 stability, and increased WNT signaling [21,22]. As both cyclin D1 
expression and WNT signaling have been implicated in a variety of cancers [20], the ability 
of Laforin to regulate GSK3β to inhibit cyclin D1 and WNT signaling is a possible 
mechanism by which Laforin may function as a tumor suppressor. In addition to a GSK3β-
dependent role in promoting cell cycle progression [21,22], Laforin additionally possesses 
pro-survival attributes and may be a potential therapeutic target in lymphomas where low 
Laforin expression promotes apoptosis induced by energy deprivation, while lymphomas 
with high Laforin expression are resistant [18]. Laforin's ability to promote cell survival 
could be related to glycogen metabolism, or alternatively due to its indirect regulation of the 
WNT signaling pathway via activation of GSK3β [18,19].  
Laforin additionally has a role in stress induced proteostasis [23-26].  Knock down of Laforin 
in human embryonic kidney (HEK293) cells and the neuroblastoma cell line, SH-SY5Y, 
 Oncogene and Cancer – From Bench to Clinic 96 
resulted in increased apoptosis induced by endoplasmic reticulum (ER) stress [24]. Laforin 
also promotes autophagy by inhibiting the mammalian target of rapamycin (mTOR) 
pathway by a currently unknown mechanism to further protect cells from ER stress [25]. In 
addition to targeting genes involved in glycogen metabolism, recruitment of Malin further 
promotes ubiquitination of misfolded and aggregated proteins, thereby facilitating their 
proteosomal degradation [27]. Laforin also interacts with heat shock factor 1 (HSF1), an 
essential transcription factor in the heat shock response [26] and is necessary for up-
regulation of HSF1-dependent gene expression and for protection from thermal stress in 
COS7 cells [26]. Accordingly, increased Laforin expression may allow cancer cells to survive 
in conditions where proteostasis has been perturbed.  
2.2. DUSP3/VHR 
Despite the ability of DUSP3 (alternatively named VHR for VH-1 related) to 
dephosphorylate the ERK1/2 and JNK MAPKs, it is generally not considered a MKP as it 
lacks the MAPK binding domain characteristic of MKPs [2,28,29].  Nevertheless, as a 
functional MAPK phosphatase, it is not surprising that DUSP3 is implicated in cancer, 
where it has been alternatively described as having both oncogenic [30-32] and tumor 
suppressive [33,34] properties.  
dusp3 is up-regulated in cervical cancer cell lines and primary cervical cancers [30], and in 
HeLa cells, knock-down of dusp3 inhibited proliferation by increasing the phosphorylation 
levels of ERK1/2 and JNK [31,35]. dusp3 is also over-expressed in primary prostate tumors 
where it may function as a pro-survival phosphatase [32]. In prostate cancer cells (LNCaP), 
DUSP3 functions as an inhibitor of apoptosis, where dusp3 knock-down resulted in 
increased JNK phosphorylation and increased apoptosis when treated with thapsigargin, an 
inducer of ER stress, or 12-0-tetradecanoylophorbol-13-acetate (TPA) [31]. 
DUSP3 may also inhibit tumor growth by regulating proliferation, particularly in the 
context of breast cancer cells expressing the oncogene, brca1-iris. brca1-iris is a splice variant 
of the breast cancer type 1 susceptibility (brca1) locus that promotes cell proliferation, cell 
migration, and invasion [34,36]. Over-expression of brca1-iris in breast cancer cell lines 
MCF7 and SKBR3 promoted proliferation through up-regulation of cyclin D1, and over-
expression of dusp3 was sufficient to suppress cyclin D1 expression [34]. dusp3 expression is 
also down-regulated in primary  non-small cell lung cancer (NSCLC) tumors [34]. A tumor 
suppressive function for DUSP3 in NSCLC is supported experimentally, as in both the 
NSCLC H1299 cell line and mouse xenographs, over-expression of dusp3 suppressed growth 
of cells and tumors respectively [32]. Further supporting a tumor suppressor function for 
DUSP3, its expression suppressed phospholipase C (PLC) - protein kinase C (PKC) signaling 
[36]. The ErbB tyrosine kinase receptor, known to act upstream of PLC-gamma was 
subsequently identified as a direct DUSP3 substrate [37]. Increased ErbB tyrosine kinase 
activity drives several cancer-relevant properties including proliferation, cell motility, and 
invasion [36]. dusp3 over-expression removed the activating phosphate from Y992 of ErbB, 
preventing ErbB kinase activity [33]. As the ErbB family of proto-oncogenes is strongly 
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associated with cancers in a kinase dependent manner [37], the ability of DUSP3 to inhibit 
its activity may have important implications for cancer therapies. 
If DUSP3 functions as a tumor suppressor or oncogene, modulators of DUSP3 function(s) 
could be attractive anti-cancer drug targets. The ZAP70 cytoplasmic tyrosine kinase, a key 
component in signaling machinery downstream of the T-cell antigen receptor, directly 
phosphorylates DUSP3  on  tyrosine 138 (Y138) and increases it's ability to temper Erk1/2 
and JNK signaling and reduce expression of a NFAT-AP1 dependent luciferase reporter, as 
VHRY138F functions as a dominant negative [38].  This observation is consistent with Y138 
increasing the catalytic activity VHR, but this hypothesis is technically difficult to confirm 
due to VHR's ability to auto-dephosphorylate [38].  ZAP70 has been implicated in cancer as 
it is a prognostic marker for chronic lymphocytic leukemia (CLL) and B-cell acute 
lymphoblastic leukemia (B-ALL) where increased ZAP70 expression correlates with poor 
clinical outcome [39,40]. Besides being a prognostic marker, ZAP70 contributes to cancer by 
promoting survival and migration in both CLL and B-ALL [41,42] but whether ZAP70's 
modulation of DUSP3 has importance in B-ALL and CLL remains unknown. ZAP70 is not 
the only tyrosine kinase to target DUSP3 at tyrosine 138. TYK2, the non receptor tyrosine 
kinase of the Janus kinase family that regulates the expression of type 1 interferons and 
interleukin 12 [43] also targets this site [44]. Phosphorylation of DUSP3 by TYK2 was 
required for DUSP3 to dephosphorylate and inhibit signal transducer and activator of 
transcription 5 (STAT5) [44]. The ability of DUSP3 to inhibit STAT5 transcriptional activity 
may have consequences in cancer cell biology, since STAT5 activity is known to promote 
cancer by transcriptionally regulating genes involved in proliferation and survival [45], 
therefore loss of DUSP3 activity could possibly result in increased STAT5 activity thereby 
promoting cancer development. Furthermore, TYK2 has a suggested role in breast cancer 
metastasis, as analysis of 140 tissue samples from 70 breast cancer patients revealed that 
TYK2 protein levels are reduced in tumors that have metastasized to the regional lymph 
nodes [46]. Additionally, knock-down of tyk2 in the MCF10A breast epithelial cell line 
decreased cell migration and invasion [46]. Whether loss of TYK2 promotes metastasis, 
migration, and invasion due to reduced DUSP3 activity remains to be determined 
DUSP3’s activity is additionally activated by the pseudokinase, Vaccinia-related kinase 3 
(VRK3) [47], whose expression is down-regulated in colorectal cancer [48]. VRK3 inhibits 
ERK1/2 signaling by the formation of a VRK3-DUSP3-ERK1/2 complex where VRK3 is able 
to enhance the activity of DUSP3 towards ERK1/2 in a kinase independent manner [47]. It 
would be interesting to examine whether tumors with decreased vrk3 expression also have 
decreased DUSP3 activity. Since VRK3 promotes DUSP3’s activity towards ERK1/2, one 
would expect tumors with decreased VRK3 to have increased ERK1/2 signaling, and these 
investigations could further indicate a potential tumor suppressor for DUSP3. 
2.3. DUSP11 
Due to interactions with ribonucleoprotein (RNP) complexes and RNA splicing factors and 
its ability to dephosphorylate RNA trinucleotides, DUSP11 is thought to have a role in RNA 
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splicing [49]. DUSP11 also associates with SAM68 (SRC-associated protein in mitotic cells), 
an ERK1/2 phosphorylated splicing factor that promotes the alternative splicing of cluster of 
differentiation 44 (CD44) mRNA encoding a glycoprotein involved in cell-cell interactions, 
cell adhesion, and migration [50,51].   Alternatively spliced isoforms of CD44 include up to 
10 variant exon sequences (V1 to V10) that are though to contribute to human organismal 
complexity from a relatively restricted number of genes [50].   The v5 exon splice variant of 
CD44 is suggested to promote metastatic cancers [50,51] and this alternative splicing event is 
thought to be under the control of Ras singaling pathway through recruitement of SAM68.  
As forced overexpression of Sam68 leads to increased inclusion of the V5-exon sequence in 
CD44 and Dusp11 associated with SAM68, and variants of SAM68 that cannot be 
phosphrylated by ERK abrogate the inclusion of the V5-exon variant, it suggests that SAM68 
function is under control of Ras signaling pathways in response to extracellular cues, but 
whether DUSP11 can counteract the ERK1/2 dependent phosphorylation of SAM68 similar 
to Sam68 varaints lacking all candidate ERK1/2 phosphorylation sites remains to be 
determined experimentally. As alternative splicing affects the activities of many oncogenes 
and tumor suppressors, DUSP11’s role in splicing may extend beyond CD44, which could 
have important implications for cancer [52].  
dusp11 is also a transcriptional target of the p53 tumor suppressor [53]. p53 is a potent tumor 
suppressor that induces cell cycle arrest, senescence, and apoptosis in response to DNA 
damage and oncogene activation, and is one of the most commonly mutated genes in cancer 
[54]. The ability of p53 to up-regulate dusp11 may provide a link between p53 function and 
to the splicing machinery [53]. 
DUSP11 regulates proliferation as over-expression of dusp11 in U20S and mouse embryonic 
fibroblasts resulted in inhibition of proliferation in a manner dependent on DUSP11’s 
phosphatase activity [53]. Additionally, knock-down of dusp11 increased proliferation in 
both untreated and UV or Doxorubicin DNA damaged U20S cells where DUSP11 most 
likely inhibits proliferation in response to genotoxic stress in a p53 dependent manner [53]. 
Loss of growth arrest in response to DNA damage in cells lacking dusp11 could result in 
genomic instability, which can promote cancer development and/or progression [55]. 
2.4. DUSP12 
dusp12 is up-regulated or amplified in a variety of cancers including neuroblastoma, 
retinoblastoma, intracranial ependymoma, and chronic myelogenous leukemia [56-59]. 
Additionally, dusp12 is one of only two candidate genes for the target of a 1q21-1q23 
amplification found in invasive liposarcomas [60] leading to the hypothesis that dusp12 is an 
oncogene. Within the atypical DUSPs, DUSP12 is unique in that it contains an evolutionarily 
conserved cysteine-rich domain (CRD) at the C-terminus that binds zinc [61], but whose 
biological function remains obscure. 
DUSP12 was initially identified as a pro-survival phosphatase from a high throughput 
siRNA screen in HeLa cells [62] as knock-down of dusp12 induced spontaneous apoptosis 
[62]. Later, it was demonstrated that transient over-expression of dusp12 in HeLa rendered 
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cells resistant to apoptotic stimuli including heat shock, oxidative stress, and FAS death 
receptor activation, but not against the DNA damage inducing agent, cisplatin [63]. In HeLa 
cells, the ability of DUSP12 to protect cells from apoptosis was dependent on phosphatase 
activity [63]. 
DUSP12 interacts with the heat shock protein 70 (HSP70) and the requirement of the 
enzymatic activity to protect cells from apoptosis activity raises the possibility that HSP70 
may be a direct  substrate for DUSP12.  However, if DUSP12 does regulate HSP70, it does 
not appear to regulate HSP70’s chaperone function as demonstrated by in vitro folding 
assays [63]. Conversely, HSP70 was able to promote DUSP12’s phosphatase activity against 
the phospho-tyrosine analog, 6,8-di-fluoro-4-methylumbeliferyl phosphate (DiFMUP), in a 
manner that is most likely not a chaperone:substrate interaction as DUSP12 binds the 
ATPase domain of HSP70 [63]. The C-terminal CRD was also required for DUSP12 to 
protect from apoptosis [63]. As oxidation of catalytic cysteines is a common mechanism to 
post-translationally regulate DUSP's [64], it was later demonstrated that the zinc binding 
ability of the C-terminus protected DUSP12’s phosphatase activity during oxidizing 
conditions in vitro [65].  
DUSP12 also has a role in cell cycle regulation. Transient over-expression of dusp12 in 
HEK293 cells resulted in an increase in the percentage of cells in the G2/M phase and 
polyploidy and knock-down resulted in cell cycle arrest and senescence [66]. Since, dusp12 is 
amplified in several cancers [56,57,60], it is possible that DUSP12 may promote cancer by 
increasing genomic instability. Unlike the pro-survival properties described above, 
DUSP12's effect on the cell cycle was independent of its phosphatase activity and required 
the CRD domain [66]. The CRD function is also likely regulated post-translationally: 
replacement of serine 335 with alanine (S335A) elicited cell cycle profiles similar to wild type 
DUSP12, whereas the phosphomimetic S335E variant led to a significant increase in the 
percentage of G2/M cells (29.8 % for S335A vs. 36.6 % for S335E) [66]. This alteration also 
affects subcellular localization from the cytoplasm (WT and S335E) to the nuclear 
compartment (S335A), but does not affect DUSP12’s phosphatase activity in vitro [66]. To the 
best of our knowledge this is the only study demonstrating phosphorylation dependent 
regulation of DUSP12  and the kinases and/or  phosphatases responsible remain unknown. 
Additionally, The S335 kinases may be restricted to mammals, as the S335 site is not well 
conserved in other organisms [66].  
To determine whether DUSP12 has oncogenic properties, we examined the oncogenic 
potential of DUSP12 in a cell culture model [67]. Unlike the cell cycle effects in HEK293 cells 
transiently over-expressing dusp12 described above, we observed no difference in 
proliferation in HEK293 cells stably over-expressing gfp-dusp12 (hereafter referred to as 
dusp12 over-expression) [67]. Despite the lack of effect on proliferation, we did find that 
dusp12 over-expression protected cells from apoptosis induced by both staurosporine and 
thapsigargin [67]. We additionally observed, that dusp12 over-expression increased cell 
motility in scratch wound and transmigration assays [67]. dusp12 over-expression also up-
regulated the expression of two validated oncogenes; integrin alpha 1 (itga1) and the 
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hepatocyte growth factor receptor, c-met [67]. ITGA1, a component of the cellular receptor 
for collagen, promotes proliferation, invasion, and angiogenesis of cancer cells [68-70], but 
whether it is responsible for the DUSP12 dependent motility remains to be determined. The 
c-MET proto-oncogene is a well established regulator of growth, survival, and migratory 
signaling [71], but it seems unlikely that c-MET is responsible for the pro-survival and 
migratory function of DUSP12 overexpression, since we failed to observed increased c-MET 
activation in cells over-expressing dusp12 [67]. This was not wholly unexpected as c-MET 
frequently requires its ligand, HGF, to be supplied in an autocrine or paracrine manner in 
order to function [72]. The ability of elevated DUSP12 to promote c-MET and ITGA1 
expression has potential implications in cancer where, in the right tumor microenvironment, 
DUSP12-dependent up-regulation could co-opt the oncogenic potential of these validated 
oncogenes [73]. 
Although it is clear that DUSP12 regulates several important cancer-relevant processes, how 
DUSP12 accomplishes this is largely unknown. Insights into DUSP12’s cellular function(s) 
can be obtained by investigating the budding yeast DUSP12 ortholog, Yvh1p. YVH1 
transcription is up-regulated by nitrogen starvation and low temperatures and yvh1Δ yeast 
strains exhibit a severe growth phenotype, display defects in sporulation, glycogen 
accumulation, and ribosome biogenesis [74-78]. Expression of the Yvh1p CRD domain in 
isolation was able to suppress all the mutant phenotypes of yvh1Δ strains, suggesting that 
neither phosphatase activity nor the N-terminal phosphatase domain is required for its 
cellular function in yeast [76]. The DUSP12 CRD has been alternatively described as a LIM-
domain, a zinc-finger and a RING-variant domain due to its ability to coordinate zinc, but 
how it contributes to biological function is not clear [61]. However, either full-length human 
DUSP12 or a variant rendered catalytically inactive (C115S) were able to suppress the yvh1Δ 
phenotypes, suggesting that these proteins are functional orthologs [61]. It is important to 
note that to date, unlike human DUSP12, phosphatase-dependent function(s) of Yvh1p have 
yet to be characterized, suggesting that, DUSP12 has acquired additional cellular functions 
than those described in yeast.  
Recent independent genetic screens in yeast have revealed that Yvh1p is a critical factor in 
ribosome biogenesis [77,78]. Ribosome biogenesis is an extremely complex process that is 
regulated both spatially and temporally [79]. Ribosomal RNA is transcribed and processed 
in the nucleolus and the pre-40S and pre-60S subunits, are assembled in the nucleus [79]. 
The pre-40S and pre-60S subunits are exported into the cytoplasm where additional 
maturation occurs including the binding of multiple translation initiation factors to the 
small ribosomal subunit to form a 48S complex [79]. Upon recognition of the Met initiation 
anticodon, the translation initiation factors are expelled to facilitate the joining of the large 
60S ribosomal subunit to form a translationally competent 80S ribosome [79]. Defects within 
specific steps or association of proteins with defined complexes within this multistep 
process can be inferred from polysome analyses as each complex in endowed with a unique 
sedimentation coefficient within sucrose gradients [80]. Polysome analysis in yeast 
demonstrated that Yvh1p associates with pre-60S ribosomes and loss of YVH1 results in an 
increase in half-mers (consisting of a 48S small subunit that fails to join to a large 60S 
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ribosomal subunit) [81]. The production of translationally incompetent half-mers likely 
results from defects in cytoplasmic 60S maturation [80,81]. In addition to specific temporal 
associations of initiation factors with the 40S subunit, the nuclear pre-60S subunits associate 
with Mrt4p, which is subsequently displaced by the P0/P1/P2 ribosomal stalk proteins upon 
export of the complex into the cytoplasm [78, 82]. The addition of the ribosomal stalk to the 
cytoplasmic 60S ribosomal subunits is one of the last essential steps prior to large subunit 
joining [82]. In yvh1 null yeast strains Mrt4p remained associated with the cytoplasmic 60S 
subunits preventing the assemblage of the P0/P1/P2 proteins that form the ribosomal stalk 
[78]. Further supporting a genetic interaction between YVH1 and MRT4, specific mutations 
of mtr4 suppressed all yvh1Δ phenotypes, suggesting that the pleiotropic phenotypes 
associated with yvh1Δ strains may be an indirect consequence of aberrant ribosome 
maturation [83]. 
A similar role for DUSP12 regulating ribosome biogenesis in humans is borne from 
observations that knock-down of human dusp12 in HeLa cells promoted the mislocalization 
of the ribosome factors MRTO4 and eIF6, a translation initiation factor that also binds to the 
60S subunit preventing its association with the 40S subunit [84]. In addition, siRNA knock-
down of the ribosome factor P0 in HeLa cells resulted in exclusion of DUSP12 from the 
nucleus [84], its initially characterized sub-cellular localization [61]. As was described in 
yeast, the reported pleiotropic roles for human DUSP12 may also be an indirect consequence 
of defects in the production of translationally competent ribosomes, as several proteins 
affecting ribosome biogenesis are known oncogenes [85] and many other oncogenes are 
selectively regulated at the translational level [86].  
2.5. DUSP18 
dusp18 mRNA is expressed in a variety of primary tumors and cancer cell lines [87]. The 
crystal structure of DUSP18 demonstrates that the phosphatase domain adopts a structure 
similar to the phosphatase domain of DUSP3/VHR with some minor modifications, 
including alterations in charge distribution within the active site pocket, suggesting the 
possibility that it may have distinct substrate specificity profile [88]. Additionally, DUSP18 
contains a C-terminal motif (CT) that specifically interacts with the catalytic domain, which 
may be responsible for Dusp18's elevated thermostability, with a temperature optimum of 
55°C [89]. DUSP18 localizes to the nuclear and cytoplasmic compartments as well as the 
intermembrane space of the mitochondria [90,91] although it appears that the 
mitrochondrial localization is native as reports of DUSP18 localizing to the cytoplasm and 
nucleus was due to over-expression of dusp18 with an N-terminal tag that disrupted the 
mitochondrial localization [91]. Like components of the intrinsic pathway of apoptosis, 
mitochondrial DUSP18 can be released into the cytoplasm in response to apoptotic signals 
[91]. DUSP18 selectively dephosphorylates the JNK stress activated MAPK in vitro and in 
vivo [87,90,91], but since JNK is not thought to be mitochondrially resident, it seems unlikely 
that DUSP18 interacts with JNK under normal conditions [91]. However, due to the ability 
of intrinsic apoptosis to release DUSP18 from mitochondria, it is possible that DUSP18 may 
be able to interact with and dephosphorylate JNK under apoptotic conditions. The JNK 
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MAPK is a well-established regulator of tumorigenesis, and regulates processes such as cell 
proliferation [92], apoptosis [93], and inflammation [94]. 
2.6. DUSP22 
DUSP22 expression is down-regulated in breast cancer and lymphomas [95, 96], and is used 
as a prognostic marker for B cell chronic lymphocytic leukemia patients [97]. In anaplastic 
lymphoma kinase (ALK)-negative anaplastic large cell lymphomas, the commonly found 
t(6;7)(p25.3;q32.3) translocation disrupts the dusp22 gene [96]. Down-regulation of dusp22 in 
cancer suggests a possible tumor suppressive role for DUSP22, but exactly how DUSP22 
may function in cancer and normal cell biology awaits further characterization. 
There are conflicting reports concerning the ability of DUSP22 to dephosphorylate MAPKs 
[97-100], but most studies indicate DUSP22 as a regulator of JNK [99-101]. Over-expression 
of both JNK and DUSP22 in COS7 suppressed JNK phosphorylation [99]. However, other 
reports have identified a phosphatase-dependent role for DUSP22 in promoting JNK activity 
[100,101]. Glutathione S-transferase (GST) pull downs and immunoprecipitations revealed 
that DUSP22 can bind the JNK activating kinase, MKK7, but not JNK itself, and the 
association with MKK7 activates MKK7's phosphorylation of JNK [99]. Exactly how DUSP22 
activates MKK7 and JNK activity is unclear but the requirement is biologically significant as 
mouse embryonic stem cells lacking DUSP22 were unable to activate JNK in response to 
cytokines [100].  
Another reported substrate of DUSP22 is the estrogen receptor (ERα) an important 
prognostic marker for breast cancer regulating proliferation and apoptosis [102,103]. 
DUSP22 most likely functions within a negative feedback loop to regulate ERα, as activation 
of ERα induces dusp22 mRNA expression and DUSP22 dephosphorylates and inhibits ERα’s 
transcriptional activity in breast cancer cells [102]. Additionally, dusp22 expression is down-
regulated in breast cancers, specifically those containing the 8p11-12 amplicon [95]. This 
amplicon contains the potential oncogene, ppapdc1b, which is thought to be responsible for 
DUSP22 down-regulation as siRNA knock-down of ppapdc1b increases dusp22 expression 
[95]. The oncogenic ability of ppapdc1b, in part, may be due to its ability to down-regulate 
dusp22 expression to allow for increased estrogen receptor activity, as it was reported that all 
11 tumor samples analyzed that contain the 8p11-12 amplicon, had ER-positive statuses [95]. 
DUSP22 may also regulate metastasis as it dephosphorylates tyrosines 576/577 and 397 of 
focal adhesion kinase (FAK) [104]. FAK is a key regulator of integrin-mediated attachment 
and FAK inhibition results in detachment and apoptosis in some cell lines [105]. dusp22 
over-expression inhibited cell migration and reduced FAK phosphorylation while dusp22 
knock-down promoted cell migration and FAK phosphorylation in H1299 cells [104]. 
DUSP22 is myristoylated [106], which may allow for its co-localization with FAK at actin 
filament enriched regions of lamelapodia [104]. The subcellular localization of DUSP22 
likely contributes to its biological function as myristoylation-deficient variants of DUSP22 
do not display altered enzymatic activity in vitro, but unlike wild-type DUSP22, induced cell 
detachment and apoptosis when over-expressed [106].  
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2.7. DUSP23 
DUSP23 dephosphorylates ERK1/2 in vitro, but DUSP23 is an activator of JNK and p38 in 
COS7 cells [6]. In addition, the regulation of JNK and p38 is phosphatase independent, and 
the MAPKKs for JNK and p38, MKK4 and MKK6, also have increased phosphorylation 
when dusp23 is over-expressed and the cells are treated with sorbitol,  suggesting that 
DUSP23 may act as a scaffold to promote MKK binding to JNK and p38 [6]. 
The dusp23 gene is highly methylated and decreased dusp23 mRNA expression is observed 
in neuroblastoma [107]. Interestingly, dusp23 mRNA levels were lower in tumors from 
deceased patients than patients exhibiting no clinical symptoms, suggesting that DUSP23 
levels could be a prognostic marker for neuroblastomas [107]. The generality of dusp23 
functioning as a tumor suppressor is called into question by observations that it is amplified 
in many other cancers, including breast, colon, lung, squamous carcinoma, pancreatic, brain, 
esophageal, stomach, bladder, kidney, skin, ovary, prostate, and testicular cancers [108], and 
selective over-expression of dusp23 in MCF7 cells increased proliferation while knock-down 
of dusp23 decreased proliferation [108]. 
2.8. DUSP26 
A role for dusp26 in cancer is borne by observations that it is located on an 8p12 amplicon 
found in anaplastic thyroid carcinoma tissue [109] and differential expression of dusp26 has 
additionally been observed in glioblastoma tissues, neuroblastoma, brain, and ovarian 
cancer cell lines, where dusp26 is down-regulated [110,111]. Additionally, knock-down of 
dusp26 in immortalized ovarian epithelia HOSE17.1 cells increased both colony formation 
and proliferation [111]. Over-expression of dusp26 in immortalized breast epithelial 
MCF10A, cells suppressed colony formation and acinar growth in 3D culture [111]. 
Alternatively, in anaplastic thyroid carcinoma primary tumors and cell lines, over-
expression of dusp26 promoted colony formation, while knock-down of dusp26 expression 
reduced proliferation [109]. Defining a more precise role for DUSP26 is further complicated 
by the fact that different groups have come to opposing conclusions regarding dusp26 
expression in neuroblastoma cell lines [111,112]. 
The cellular function of DUSP26 is also unclear as the substrates for DUSP26 are debated. 
DUSP26 can dephosphorylate the tumor suppressor p53 at Ser20 and Ser37, inhibiting p53-
mediated apoptosis induced by genotoxic stress [112], suggesting a pro-survival role. In 
addition to p53, several other in vitro DUSP26 substrates have been described, including p38 
[109]. In HEK293T cells, over-expression of dusp26 resulted in reduction of p38 activity and 
p38-mediated apoptosis [113]. The small molecule inhibitor NSC-87877 functions as an in 
vitro DUSP26 inhibitor with an IC50 of 16.7 uM that additionally prevented the DUSP26-
dependent dephosphorylation of p38 in HEK293 cells [114]. However, in COS7 cells, over-
expression of dusp26 increased both JNK and p38 activities [6], and in the rat neuronal cell 
line, PC12, and epithelial cells DUSP26 had no affect on MAPKs [17,112] questioning the 
generality of DUSP26 functioning as a p38 phosphatase. 
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DUSP26 is also implicated in regulating the kinesin superfamily 3 (KIF3) microtubule-
directed protein motor complex by dephosphorylating the kinesin-associated protein 3 
(KAP3) [111]. The KIF3 motor complex has been implicated in cancer due to its ability to 
traffic cancer relevant proteins including, adenamaous polyposis coli (APC), β-catenin, 
cadherins, and the polarity complex, PAR3 [115,116]. Consistent with DUSP26 functioning 
as a positive regulator of KIF3, over-expression of dusp26 in the mouse fibroblast cell line, 
NIH3T3, increased cell-to-cell adhesion and intracellular transport of N-cadherin and β-
catenin to the cell surface [111].  
3. Less well-characterized atypical DUSPs. 
The previous sections discussed the atypical DUSPs that have been described in the 
literature as having a relationship, however tenuous or controversial, to tumor suppressive 
and/or oncogenic properties and are often supported by genetic/genomic analyses of 
primary tumors samples. Although the previous sections should reaffirm that the 
function(s) of many of the atypical DUSPs are likely both cell type and context dependent, 
we nevertheless undertook a comparison of the expression profiles of all the atypical DUSPs 
in tumors of the prostate to normal prostate tissue using the cBio Cancer Genomics Portal 
(http://www.cbioportal.org/) and microarray data deposited by the Memorial Sloan-
Kettering Cancer (MSKCC) Center’s Prostate Oncogenome Project [117]. Comparison of the 
transcriptome of 85 tumors to normal prostate tissue revealed that many atypical DUSPs 
have aberrant expression in prostate cancer (Table 2). In at least two cases this difference  
 
Gene Down Up Total 
EPM2A 13% 0% 13% 
STYX 2% 7% 9% 
DUSP3 40% 0% 40% 
DUSP11 4% 5% 8% 
DUSP12 1% 15% 16% 
DUSP13 0% 5% 5% 
DUSP14 6% 11% 16% 
DUSP15 4% 0% 4% 
DUSP18 40% 4% 44% 
DUSP19 1% 1% 2% 
DUSP21 0% 7% 7% 
DUSP22 15% 2% 18% 
DUSP23 11% 8% 19% 
DUSP26 1% 2% 4% 
DUSP27 2% 5% 7% 
Androgen Receptor (AR) 2% 7% 9% 
Table 2. Using the cBio Cancer Genomics protal (http://www.cbioportal.org/), and microarray data 
deposited by MSKCC Prostate Oncogenome Project [117]. we compared the expression of atypical 
DUSPs in tumors to normal prostate tissue using a Z score threshold of +/- 2.  The androgen receptor 
(AR) is included for comparison as a gene already implicated in cancer progression [117] 
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was reflected clinically as patients harboring tumors with aberrant dusp22 or dusp23 
expression had faster disease relapse than those harboring tumors with normal dusp22 or 
dusp23 expression (Figure 1). Although differential expression of any particular gene in 
prostate cancer may not functionally contribute to the initiation or progression of the 
disease, this analysis serves as an example of one way to potentially identify cancer-relevant 
markers. The following sections describe what is currently known about the remaining 
atypical DUSPs that, to date, have not been specifically associated with cancer. 
 
Figure 1. Kaplan-Meyer analysis of disease free survival for patients with altered expression of the 
androgen receptor or atypical DUSPs. This graph was generated by the cBio Cancer Genomics Portal 
(http://www.cbioportal.org/) using data deposited by the MSKCC Prostate Oncogenome Project [117]. 
Microarray expression data from tumors compared to normal prostate was used in this analysis with a 
Z-score threshold of +/- 2. 
3.1. STYX 
The prototypical pseudophosphatase, STYX, contains a substitution of the catalytic cysteine 
for glycine, rendering it catalytically inactive [118]. As this mutation abrogates catalysis, but 
not substrate binding, pseudophosphatases are though to function as substrate traps 
preventing dephosphorylation of the target protein(s) [119]. In mice, styx expression is 
restricted to the testis, and is essential for spermatogenesis, as STYX knock-out male mice 
are infertile [118]. 
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3.2. DUSP13A/B 
The dusp13 gene encodes for two similar protein products via alternative reading frames 
[120,121]. Designated DUSP13A and DUSP13B, the proteins are expressed in the muscle and 
testis respectively [121,122]. Both proteins have phosphatase activity in vitro, with DUSP13B 
exhibiting higher activity than DUSP13A [122]. Interestingly, both DUSP13A and B regulate 
apoptosis, but by different mechanisms. Knock-down of DUSP13A in mouse embryonic 
fibroblasts reduced apoptosis signal regulating kinase 1 (ASK1) kinase activity and intrinsic 
apoptosis induced by ask1 over-expression [7]. Furthermore, autophosphorylation assays of 
ASK1 with increasing amounts of DUSP13A demonstrated that DUSP13A increases ASK1 
autophosphorylation in a phosphatase independent manner [7]. In contrast to DUSP13A, 
DUSP13B appears to be pro-survival [123]. Over-expression of DUSP13B in COS7 cells 
resulted in reduced phosphorylation of the stress activated MAPKs, JNK and p38 [123]. 
Over-expression of DUSP13B resulted in reduced activity of the down-stream JNK effector 
AP-1 in a phosphatase dependent manner [123]. AP-1 activity is associated with a large 
number of cellular processes including transformation, proliferation, differentiation, and is 
specifically implicated in apoptosis [124]. 
3.3. DUSP14 
dusp14 is located on a chromosomal region that is amplified in gastric cancer,  but it may not 
be the target for the genetic amplification, as dusp14 expression is not increased [125]. In 
vitro, DUSP14 dephosphorylates all three MAPK isoforms, leading to its alternate 
designations of  MKP-L (MKP1-Like) and MKP-6 [126]. However, DUSP14 is classified as an 
atypical DUSP as it lacks the characteristic MAPK binding domain found in the MKP DUSP 
subfamily [2]. In T-cells, expression of the catalytically inactive DUSP14 C111S variant 
enhanced ERK1/2 and JNK phosphorylation, suggesting that in vivo, p38 is not a DUSP14 
substrate [126]. Additionally, in β pancreatic cells, knock-down of dusp14 expression or the 
expression of a dominant negative DUSP14 variant resulted in increased ERK1/2 
phosphorylation and cell proliferation [127].  Elucidating a role for DUSP14 may be aided by 
the discovery of the PTP inhibitor IV, an inhibitor of DUSP14 in vitro that increases 
hydrogen peroxide induced JNK activation in a concentration dependent manner [128]. 
3.4. DUSP15 
The DUSP15 crystal structure reveals it lacks the MAPK substrate recognition domain and it 
has a unique additional alpha helix located at the back end of the active site suggesting that 
DUSP15 has unique substrate recognition mechanisms [129]. DUSP15 displays phosphatase 
activity against the artificial substrate pNPP in vitro [130], but physiological substrates for 
DUSP15 have yet to be reported. DUSP15 contains an N-terminal myristoylation signal, 
resulting in targeting of the protein to plasma membrane [90] and in mice DUSP15 has been 
identified as a candidate gene in a quantitative trait locus (QTL) thought to harbor genes 
that control for the predisposition to growth and fatness in mice [131].  
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3.5. DUSP19 
Like DUSP13A, DUSP19 is thought to facilitate ASK1 activation leading to MKK7 activation 
and in turn activating JNK as DUSP19 directly binds MKK7, but not JNK in vitro, and co-
immunoprecipitates with ASK1 and MKK7 [8,132]. The proposed model for how DUSP19 
differentially regulates JNK activation is that at high levels of DUSP19 ASK1 is sequestered 
by DUSP19 thereby inhibiting MKK7 and JNK activation, while at low levels DUSP19 
functions as a scaffold to promote the activation of MKK7 by ASK1 [8,132]. 
3.6. DUSP21 
Similar to DUSP18, DUSP21 contains a highly conserved mitochondrial localization signal, 
however DUSP21 localizes to the peripheral membrane of the inner membrane of the 
mitochondria, which is the opposing side to which DUSP18 is found [91]. DUSP21 exhibits 
activity against synthetic MAPK peptides in vitro, but cell based assays fail to demonstrate 
that DUSP21 has activity against any cellular MAPKs [90]. 
3.7. DUSP27 
Substrates for the newest atypical DUSP, DUSP27, are unknown but solution of the DUSP27 
3D structure suggests that it may have substrates other than the MAPKs [133]. The catalytic 
site can accommodate dually-phosphorylated residues separated by two amino acids, which 
differs from the catalytic site of DUSPs that can dephosphorylate the characteristic MAPK 
activation loop (T-X-Y) [133].  
4. Conclusion 
Although many atypical DUSPs display differential expression in tumor samples, significant 
amounts of work will be required to determine whether and how these differences 
contribute to malignancy, especially with the common discrepancy between in vitro and in 
vivo results. Due to the central localization of the MAPK signaling cascade and the role of 
MKPs in malignancy, much of the initial work has been to evaluate if and how atypical 
DUSPs affect MAPK signaling. The MAPK pathway however represents a doubled edged 
sword, although it is strongly associated with disease, it is difficult to modulate 
pharmacologically due to complex crosstalk and feedback loops. We envision that specific 
inhibitors for atypical DUSPs, particularly those that do not target MAPK isoforms but other 
cancer-relevant substrates, could have important therapeutic value. Even in the event that 
these inhibitors fail to function as therapeutics, we think that selective inhibitors will be 
instrumental in advancing the elucidation of the cellular functions, substrates, and 
expression of the atypical DUSPs. Even in instances where the mechanism of oncogenesis 
remains unknown, we anticipate that continued large-scale expression profiling of the 
atypical DUSPs may be increasingly used to for clinical benefit to patients through the 
identification of potential novel biomarkers. 
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